Safety and antitumor activity of the first-in-class EGFR-HER3…
A novel two-target cancer drug shows promise in patients whose tumors resisted prior treatments, potentially opening new avenues when single-target approaches fail.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma
CAR-T cell therapy for hard-to-treat myeloma provides good value compared to standard care, supporting insurance coverage for more patients earlier.
Early cancer detection or preventionEvaluation of a Tumor-Informed Molecular Residual Disease Assay in…
Blood tests detecting cancer DNA fragments predict relapse risk in triple-negative breast cancer, helping doctors tailor follow-up treatment intensity.
Near-term implementable findingPredicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease
Machine learning models using brain imaging and blood markers identify people with mild memory loss likely to develop Alzheimer's disease within years.
Novel or significantly improved treatmentInternational expert panel review for the use of resmetirom and…
New liver disease medications backed by FDA approval now have expert guidance on selecting patients and monitoring safety in real-world practice.